Nautilus to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
SEATTLE–(BUSINESS WIRE)–Nautilus Biotechnology, Inc. (“Nautilus Biotechnology” or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference.
Nautilus’ management is scheduled to present on Thursday, June 10th at 3:00 p.m. Eastern Time/12:00 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the company’s website at: https://investors.nautilus.bio
About Nautilus Biotechnology, Inc.
Nautilus is a biotechnology company who is developing a proteomics platform that aims to deliver superior sensitivity more quickly, more completely, and less expensively than is currently possible. Nautilus Biotechnology aims to enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and enhance opportunities for personalized and predictive medicine. Nautilus’ corporate headquarters is in Seattle, Washington and scientific research and development is being conducted from its San Carlos, California office and labs.
Contacts
Investors:
InvestorRelations@nautilus.bio
Media:
Thermal for Nautilus Biotechnology
Kaustuva Das
press@nautilus.bio
